Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 13,453 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting Phase 1 Interventional

Safe Accelerated Venetoclax Escalation in CLL

NCT04843904
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Venetoclax, Obinutuzumab, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cerebral Palsy, Arthrogryposis, Spinal Muscular Atrophy, Other Central Nervous System or Musculoskeletal Disorders
Interventions
Power mobility
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
14 Months to 30 Months
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Completed Phase 3 Interventional Results available

Homeopathic Treatment of Post-acute COVID-19 Syndrome

NCT05104749
Conditions
Post-acute Covid-19 Syndrome
Interventions
Homeopathic Medication, Placebo
Drug · Other
Lead sponsor
Southwest College of Naturopathic Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
PTSD, Alcohol Abuse, Alcoholism
Interventions
Topiramate, Placebo administration
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Conditions
Injuries, Pain
Interventions
Comprehensive Medical Management, Spinal Cord Stimulator
Other · Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
La Jolla, California
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
6
States / cities
Fresno, California • Chicago, Illinois • Omaha, Nebraska + 3 more
Conditions
Chronic Shoulder Pain
Interventions
Lidocaine 1% Injectable Solution, Triamcinolone Injection, Suprascapular Nerve Block
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Completed Phase 1 Interventional Accepts healthy volunteers

Augmentation of Locomotor Adaptation Post-Stroke

NCT02892084
Conditions
Stroke
Interventions
tDCS, Sham tDCS
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Provoked, Localized Vulvodynia, Provoked Vestibulodynia, Vulvar Vestibulitis, Vulvodynia
Interventions
Classical Acupuncture, Non-classical acupuncture, Lidocaine
Procedure · Drug
Lead sponsor
Oregon College of Oriental Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Arthritis Knee, Arthritis Hip, Chronic Pain
Interventions
opioid taper
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin
Interventions
PCI-24781
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Lafayette, Indiana + 4 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, placebo, olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
20
States / cities
Wheat Ridge, Colorado • Clearwater, Florida • Panama City, Florida + 17 more
Conditions
Leukemia, Myeloid, Chronic, Leukemia, Lymphocytic, Acute, L2
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
30
States / cities
Corona, California • Aurora, Colorado • Colorado Springs, Colorado + 27 more
Completed Phase 3 Interventional Results available

IGIV Study for Chronic ITP Patients Ages 3-70

NCT00511147
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
IGIV3I Grifols 10%
Biological
Lead sponsor
Grifols Biologicals, LLC
Industry
Eligibility
3 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 26 more
Conditions
HIV Infections, Hepatitis C
Interventions
Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
24
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Conditions
Long COVID, Long Covid19
Interventions
Narrative Intervention for Long COVID-19 (NICO)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Antihistamine, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
24
States / cities
Homewood, Alabama • Phoenix, Arizona • Irvine, California + 21 more
Conditions
Peripheral Arterial Disease, Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Aurora, Colorado • Denver, Colorado
Conditions
Chronic Hand Eczema
Interventions
Observational (Non-Interventional) Registry
Other
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
2,000 participants
Timeline
2026 – 2099
U.S. locations
1
States / cities
Waltham, Massachusetts
Completed Early Phase 1 Interventional Results available

RHD Genotype Matched Red Cells for Anti-D

NCT04156906
Conditions
Sickle Cell Disease, Anti-D Antibodies
Interventions
D+ RH genotype matched red cell units for transfusion
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI (PT003), FF MDI (PT005), GP MDI (PT001), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
44
States / cities
Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more
Conditions
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia
Interventions
allogeneic cytomegalovirus-specific cytotoxic T lymphocytes
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Active, not recruiting Not applicable Interventional

Mindfulness And Placebo for Pain (MAPP) Study

NCT06720909
Conditions
Chronic Pain
Interventions
Mindfulness-Based Stress Reduction (MBSR), Open-Label Placebo (OLP), MBSR+OLP
Behavioral · Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona
Conditions
Asthma, COPD
Interventions
beclamethasone dipropionate, albuterol, Prednisone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Buffalo, New York